SAB Biotherapeutics Warrant
SABSW
24 hedge funds and large institutions have $3.97M invested in SAB Biotherapeutics Warrant in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
44% more capital invested
Capital invested by funds: $2.75M → $3.97M (+$1.22M)
41% more funds holding
Funds holding: 17 → 24 (+7)
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$196K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$127K |
| 3 |
KC
Kepos Capital
New York
|
+$110K |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$90.7K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$83.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$54.4K |
| 2 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$29K |
| 3 |
FTCM
Fir Tree Capital Management
New York
|
-$28.2K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$25.6K |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$18.1K |
SABSW Hedge Fund Activity: Q2 2021 in Review
24 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q2 2021, worth a combined $3.97M — up 44% from $2.75M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SABSW positions and 2 closed out — a net gain of 7 holders — while 1 added to existing stakes and 7 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $196K. The largest seller was Polar Asset Management Partners, cutting an estimated $54.4K.
- 24 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q2 2021, up from 17 in Q1 2021.
- Funds reported $3.97M of SAB Biotherapeutics Warrant stock for Q2 2021, up 44% quarter-over-quarter.
- 9 funds opened new SAB Biotherapeutics Warrant positions in Q2 2021 and 2 closed out, a net change of +7 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q2 2021 was Glazer Capital LLC, an estimated $196K added.
- The largest SAB Biotherapeutics Warrant seller in Q2 2021 was Polar Asset Management Partners, an estimated $54.4K sold.
Based on aggregated 13F filings for Q2 2021.